Antibe Therapeutics Inc(Pre-Merger) ATBPF

H2s Covid

[Pragmatist]

https://journals.lww.com/shockjournal/Fulltext/2020/11000/Serum_Hydrogen_Sulfide_and_Outcome_Association_in.8.aspx

 

This is one of the few published studies (maybe the only one?) where the researchers evaluated H2S directly against covid. 

 

The researchers measured serum H2S in 74 hospitalized patients with covid pneumonia. They found that survivors had significantly higher H2S levels on days 1 and 7 after admission. And that patients who had sustained elevated H2S levels after 7 days "...had no risk of an unfavorable outcome."  Quite a bold statement for a small trial!

 

This once again shows that H2S donation might be a possible treatment for Covid-related pneumonia. Perhaps more so if it is combined with an anti-inflammatory drug?

I understand that a slow H2S release rate is critical and that perhaps Oten doesn't  meet this requirement. However, if we have a chemist onboard who specializes in developing tunable release rates....well...anything is possible. 

Just a thought.

[Doccole]

If a covid angle manifests, sky's the limit! Hope the team comes out with something in the next couple months!

[Actuarial]

The Covid thesis is a bubble - I don't believe ATE has anything to do with it. Derail from pain relief program is a waste of resources. Nasdaq uplist, fasktrack 352,  PIII 346, clinical 340, all bring us more value and certainties than Covid story.

[Doccole]

Totally disagree here.  Not a bubble.  Could be vaccinating yearly in the future.  Anything with H2s is a opportunity.  If you are short term investor, I get the narrow minded focus.

[Actuarial]

Covid might disppear overnight in a way similar to SRS did a few years ago. Pain relief program is a long run but Covid might be a short live event. If ATB-346 indeed works for Covid and Covid becomes a yearly flu, expand its indication after it receive FDA approval for chronic pain relief being still okay. 346 might work for Covid, but it might also not work for Covid, the odd is 50/50. Put

[Yellowknifer69]

Hello and good morning Longs: Can't help but not respond to this post.  Covid will never disappear and in fact Corona viruses have been with us for many decades.  This particular version is here to stay for a long time but countries will learn to adapt, vaccinate, and move forward. In my professional opinion, I would suggest that Antibe steer clear of trying to use ATB-346 for any

[Marky1]

Totally agree with you Yellow! Let's stay focused on our raison d'tre....Osteoarthritis is our claim to fame...stay focused on that, and nothing else!! Great post!

[MrMugsy]

We're working with new molecules and developing new drugs as we speak.  I don't think ATE is going to slow down going forward.  They're only going to speed up and make drug development their specialty. That's always been the plan.  IMO.

[MrMugsy]

That's the unfortunate thing ... we don't have enough info. But ... if it's about ATB-340 or Aspirin with a new delivery molecule (20 year patent) then it may have purpose as a COVID therapeutic.  Maybe a general viral therapeutic. With some luck, I'm thinking it could fast-track and leapfrog OTENA to market. Just saying ... until we know more ... there's hope. : )